0000920465-18-000002.txt : 20180103
0000920465-18-000002.hdr.sgml : 20180103
20180103215543
ACCESSION NUMBER: 0000920465-18-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171229
FILED AS OF DATE: 20180103
DATE AS OF CHANGE: 20180103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Douglass Laura L.
CENTRAL INDEX KEY: 0001589362
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36282
FILM NUMBER: 18508346
MAIL ADDRESS:
STREET 1: C/O LA JOLLA PHARMACEUTICAL COMPANY
STREET 2: LA JOLLA VILLAGE DRIVE, SUITE 1070
CITY: SAN DIEGO
STATE: CA
ZIP: 92122
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO
CENTRAL INDEX KEY: 0000920465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330361285
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-207-4264
MAIL ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
wf-form4_151503452964254.xml
FORM 4
X0306
4
2017-12-29
0
0000920465
LA JOLLA PHARMACEUTICAL CO
LJPC
0001589362
Douglass Laura L.
C/O LA JOLLA PHARMACEUTICAL COMPANY,
4550 TOWNE CENTRE COURT
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2017-12-29
4
M
0
6000
10.84
A
6000
D
Common Stock
2017-12-29
4
M
0
4000
6
A
10000
D
Common Stock
2017-12-29
4
S
0
10000
32.3208
D
0
D
Stock Option (Right to Buy)
10.84
2017-12-29
4
M
0
6000
0
D
2024-04-03
Common Stock
6000.0
0
D
Stock Option (Right to Buy)
6.0
2017-12-29
4
M
0
4000
0
D
2023-11-21
Common Stock
4000.0
14000
D
Represents the average sale price, with individual sale prices ranging from $32.29 to $32.49 per share. The reporting person will provide the Staff of the Securities and Exchange Commission or a shareholder with individual sales price information, if requested.
This option represents a right to purchase a total of 6,000 shares of the Issuer's Common Stock, one third of which shall be fully vested and exercisable on April 3, 2015, with the remaining 4,000 shares vesting quarterly thereafter over the next two years.
These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares.
/s/ Ryan Murr, by power of attorney for Laura L. Douglass
2018-01-03